Joyce Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9813915/publications.pdf

Version: 2024-02-01

94 papers	9,873 citations	61984 43 h-index	54911 84 g-index
97 all docs	97 docs citations	97 times ranked	6895 citing authors

#	Article	IF	Citations
1	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 265-275.	5.6	1,006
2	A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis. Annals of Internal Medicine, 2012, 156, 684.	3.9	918
3	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. European Respiratory Journal, 2015, 46, 976-987.	6.7	803
4	Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2010, 35, 1322-1328.	6.7	463
5	Gastroesophageal Reflux Therapy Is Associated with Longer Survival in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1390-1394.	5.6	382
6	Predicting Survival Across Chronic Interstitial Lung Disease. Chest, 2014, 145, 723-728.	0.8	366
7	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respiratory Medicine,the, 2013, 1, 369-376.	10.7	349
8	MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. New England Journal of Medicine, 2018, 379, 2209-2219.	27.0	326
9	Clinical Features and Outcomes in Combined Pulmonary Fibrosis and Emphysema in Idiopathic Pulmonary Fibrosis. Chest, 2013, 144, 234-240.	0.8	239
10	Prevalence and prognosis of unclassifiable interstitial lung disease. European Respiratory Journal, 2013, 42, 750-757.	6.7	238
11	Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1698-1702.	5.6	230
12	Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respiratory Medicine,the, 2014, 2, 557-565.	10.7	225
13	Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. , 2021, 222, 107798.		216
14	Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. European Respiratory Journal, 2012, 39, 352-358.	6.7	211
15	The Lung in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1544-1554.	5.6	198
16	Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis?. American Journal of Medicine, 2010, 123, 304-311.	1.5	183
17	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1249-1254.	5.6	166
18	Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax, 2012, 67, 407-411.	5.6	160

#	Article	IF	Citations
19	Predictors of mortality in rheumatoid arthritisâ€related interstitial lung disease. Respirology, 2014, 19, 493-500.	2.3	142
20	Pathologic Findings and Prognosis in a LargeÂProspective Cohort of Chronic Hypersensitivity Pneumonitis. Chest, 2017, 152, 502-509.	0.8	131
21	Increased Extracellular Vesicles Mediate WNT5A Signaling in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1527-1538.	5.6	127
22	Aspiration-Related Pulmonary Syndromes. Chest, 2015, 147, 815-823.	0.8	123
23	Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Annals of the Rheumatic Diseases, 2021, 80, 143-150.	0.9	120
24	Methotrexate and rheumatoid arthritis associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2000337.	6.7	114
25	Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respiratory Medicine, 2016, 119, 150-154.	2.9	111
26	Rheumatoid Arthritisâ€“associated Interstitial Lung Disease: Radiologic Identification of Usual Interstitial Pneumonia Pattern. Radiology, 2014, 270, 583-588.	7.3	109
27	Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respiratory Medicine,the, 2018, 6, 707-714.	10.7	109
28	Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 74-81.	5.6	107
29	Management of Myositis-Related Interstitial Lung Disease. Chest, 2016, 150, 1118-1128.	0.8	106
30	Targeting Interleukin-13 with Tralokinumab Attenuates Lung Fibrosis and Epithelial Damage in a Humanized SCID Idiopathic Pulmonary Fibrosis Model. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 985-994.	2.9	105
31	Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 199-208.	5.6	90
32	Idiopathic Pulmonary Fibrosis: CT and Risk of Death. Radiology, 2014, 273, 570-579.	7.3	85
33	Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respiratory Medicine, 2013, 107, 249-255.	2.9	84
34	Clinical outcomes of lung transplant recipients with telomerase mutations. Journal of Heart and Lung Transplantation, 2015, 34, 1318-1324.	0.6	82
35	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clinic Proceedings, 2019, 94, 309-325.	3.0	78
36	Female Sex and Gender in Lung/Sleep Health and Disease. Increased Understanding of Basic Biological, Pathophysiological, and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 850-858.	5.6	74

#	Article	IF	Citations
37	Comprehensive care of the patient with idiopathic pulmonary fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 348-354.	2.6	72
38	A diagnostic model for chronic hypersensitivity pneumonitis. Thorax, 2016, 71, 951-954.	5.6	70
39	A Roadmap to Promote Clinical and Translational Research in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Chest, 2014, 145, 454-463.	0.8	67
40	Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1602406.	6.7	66
41	Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1430-1444.	5.6	66
42	Mortality Risk Prediction in Scleroderma-Related Interstitial LungÂDisease. Chest, 2017, 152, 999-1007.	0.8	61
43	The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respiratory Medicine, 2017, 127, 51-56.	2.9	49
44	Risk Factors for the Development of Idiopathic Pulmonary Fibrosis: a Review. Current Pulmonology Reports, 2018, 7, 118-125.	1.3	46
45	The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation. Annals of the American Thoracic Society, 2016, 13, 1026-1033.	3.2	45
46	A Comparison of Health-Related Quality of Life in Idiopathic Pulmonary Fibrosis and Chronic Hypersensitivity Pneumonitis. Chest, 2014, 145, 1333-1338.	0.8	42
47	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2021, 204, e3-e23.	5.6	41
48	Survival in interstitial pneumonia with features of autoimmune disease: A comparison of proposed criteria. Respiratory Medicine, 2015, 109, 1326-1331.	2.9	40
49	Reflux-Aspiration in Chronic Lung Disease. Annals of the American Thoracic Society, 2020, 17, 155-164.	3.2	39
50	Interstitial Lung Disease Evaluation: Detecting Connective Tissue Disease. Respiration, 2015, 90, 177-184.	2.6	38
51	Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respiratory Medicine, 2017, 127, 1-6.	2.9	37
52	Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Related Outcome Measures, 2018, Volume 9, 321-328.	1.2	33
53	Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis. Chest, 2020, 158, 245-251.	0.8	33
54	Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial lung disease. European Respiratory Journal, 2021, 57, 2002533.	6.7	33

#	Article	IF	Citations
55	Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respiratory Research, 2012, 13, 105.	3.6	32
56	Insulin regulates alveolar epithelial function by inducing Na+/K+-ATPase translocation to the plasma membrane in a process mediated by the action of Akt. Journal of Cell Science, 2010, 123, 1343-1351.	2.0	27
57	Molecular markers of telomere dysfunction and senescence are common findings in the usual interstitial pneumonia pattern of lung fibrosis. Histopathology, 2021, 79, 67-76.	2.9	25
58	Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction. American Journal of Transplantation, 2021, 21, 2145-2160.	4.7	23
59	Chronic lung allograft dysfunction small airways reveal a lymphocytic inflammation gene signature. American Journal of Transplantation, 2021, 21, 362-371.	4.7	23
60	Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Research, 2019, 5, 00127-2018.	2.6	21
61	Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung, 2019, 197, 709-713.	3.3	18
62	Essential Components of an Interstitial Lung Disease Clinic. Chest, 2021, 159, 1517-1530.	0.8	18
63	Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Review of Clinical Immunology, 2016, 12, 509-520.	3.0	16
64	New trajectories in the treatment of interstitial lung disease. Current Opinion in Pulmonary Medicine, 2019, 25, 442-449.	2.6	16
65	CX3CR1â€“fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. European Respiratory Journal, 2020, 55, 1900460.	6.7	15
66	Connective Tissue Disease-Associated Interstitial Lung Diseases: Unresolved Issues. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 468-476.	2.1	14
67	Prospective Identification of Subclinical Interstitial Lung Disease in a Rheumatoid Arthritis Cohort Is Associated with the MUC5B Promoter Variant. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 473-476.	5.6	12
68	Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. European Respiratory Journal, 2019, 53, 1802182.	6.7	11
69	Priming With Endotoxin Increases Acute Lung Injury in Mice by Enhancing the Severity of Lung Endothelial Injury. Anatomical Record, 2011, 294, 165-172.	1.4	10
70	The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respiratory Medicine, 2015, 109, 1058-1062.	2.9	9
71	Longitudinal assessment of interstitial pneumonia with autoimmune features is encouraged. Respiratory Medicine, 2017, 132, 267.	2.9	9
72	Commercial Sexual Exploitation During Adolescence: A US-Based National Study of Adolescent to Adult Health. Public Health Reports, 2022, 137, 53S-62S.	2.5	9

#	Article	IF	Citations
73	Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT. Lancet Respiratory Medicine,the, 2014, 2, e5.	10.7	8
74	Underâ€recognised coâ€morbidities in idiopathic pulmonary fibrosis: A review. Respirology, 2016, 21, 995-1004.	2.3	8
75	Personalized medicine in interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2017, 23, 231-236.	2.6	8
76	Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clinics in Chest Medicine, 2021, 42, 295-310.	2.1	8
77	POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest, 2019, 155, 258-260.	0.8	5
78	The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1377-1378.	5.6	4
79	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. , 2014, , 349-362.		3
80	Â2 Adrenergic agonist therapy may enhance alveolar epithelial repair in patients with acute lung injury. Thorax, 2008, 63, 189-190.	5.6	3
81	Primum non nocere: Safety in clinical trials for IPF. Respirology, 2011, 16, 723-724.	2.3	2
82	FocuSSced on the Target in Systemic Sclerosisâ€“Interstitial Lung Disease: Another Arrow in the Quiver?. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 608-610.	5.6	2
83	Idiopathic pulmonary fibrosis: continuing to make progress. Lancet Respiratory Medicine,the, 2015, 3, 921-923.	10.7	1
84	Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. American Journal of Medicine, 2019, 132, e854-e855.	1.5	1
85	Cost analysis of asthma maintenance medications in a veteran population. Annals of Allergy, Asthma and Immunology, 2016, 116, 165-166.	1.0	0
86	â€œAn Ounce of Prevention . . . â€¦ Will This Be the Future for Idiopathic Pulmonary Fibrosis?. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1240-1241.	5.6	0
87	Chronic Hypersensitivity Pneumonitis (CHP), an ILD with Distinct Molecular Signatures. , 2019, , .		0
88	Urine Proteomics Identifies Novel Biomarkers of IPF Disease Progression and Resolution. , 2019, , .		0
89	Rebuttal From Drs Lee and Fischer. Chest, 2019, 155, 263-264.	0.8	0
90	Pulmonary Fibrosis and Pyoderma Gangrenosum: What's the Common Denominator?. , 2019, , .		0

#	Article	IF	Citations
91	Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease. , 2015, , .		0
92	OP0284â€…Muc5b promoter variant rs35705950 is a risk factor for rheumatoid arthritis â€“ interstitial lung disease. , 2018, , .		0
93	MUC5B is expressed by bronchoalveolar epithelia and is associated with ER stress in idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease. , 2018, , .		0
94	Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis. , 2018, , .		0